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The synthesis of oligomers containing two or three acridine units linked through 2-aminoethylglycine using solid-phase
methodology is described. Subsequent studies on cell viability showed that these compounds are not cytotoxic. Binding to several
DNA structures was studied by competitive dialysis, which showed a clear aﬃnity for DNA sequences that form G-quadruplexes
and parallel triplexes. The fluorescence spectra of acridine oligomers were aﬀected strongly upon binding to DNA. These spectral
changes were used to calculate the binding constants (K). Log K were found to be in the order of 4–6.
1. Introduction
Small organic molecules with specific interactions with DNA
have become antitumor, antiviral, and antibiotic drugs [1,
2]. Duplex DNA-binding drugs interact in two main ways,
through groove binding and through intercalation. Medic-
inal chemistry has made a considerable eﬀort in searching
for and testing of a large number of drugs with increased
selectivity to a range of DNA sequences or structures. More
recently, some of this interest has moved to the search of
new ligands for G-quadruplexes [3]. This structure motif is
formed by the planar association of four guanines in a cyclic
Hoogsteen hydrogen bonding tetrad.
Guanine-rich sequences form G-quadruplex structures
and have been found in telomeres [4] and in transcriptional
regulatory regions of critical oncogenes such as c-myc and
c-kit [5, 6]. Ligands that selectively bind and stabilize these
structures have become anticancer drugs of interest [7].
The G-quadruplex stabilization occurs in most cases
by π-π stacking and electrostatic interaction. G-quadruplex
ligands are normally planar aromatic molecules that are
prone to stacking with G-tetrads. Some of them are also
positively charged or have hydrophilic groups to favor
electrostatic interaction [8].
Although there is a long way to go in the develop-
ment of potent drugs that target G-quadruplexes, some
promising lead compounds have been achieved [9]. Several
ligand structures have been studied, such as anthraquinones,
cationic porphyrins, perylene derivatives, and a large num-
ber of compounds [9]. Among the acridine compounds,
3,6,9-trisubstituted acridines have inhibitory activity in the
nanomolar range and they have entered preclinical studies
[8, 10, 11].
In previous studies we described the preparation of
sequence specific oligomers of DNA-intercalating drugs
using protocols based on solid-phase synthesis in an attempt
to facilitate the preparation of compounds with improved
DNA-binding selectivity [12, 13]. It has been proposed that
bis- and tris-intercalating drugs show promising activity and
selectivity [14, 15]. Here we described solid-phase synthesis
protocols for the preparation of several acridine oligomers
linked through 2-aminoethylglycine units as well as their
DNA-binding properties. Although the acridine derivatives
described in this study are not cytotoxic, they show a clear
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Table 1: Sequences of oligonucleotides.
No. Name Sequence (5′–3′)
1 T20 TTT TTT TTT TTT TTT TTT TT
2 24bclc CCC GCC CCC TTC CTC CCG CGC CCG
3 Dickerson CGC GAA TTC GCG
4 Ds26 CAA TCG GAT CGA ATT CGA TCC GAT TG
5 GA triplex GAA AGA GAG GAG GCC TTT TTG GAG GAG AGA AAG + CCT CCT CTC TTT C
6 TC triplex CCT CCT CTC TTT CCC TTT TTC TTT CTC TCC TCC + GAA AGA GAG GAG G
7 TG4T TGG GGT
8 TBA GGT TGG TGT GGT TGG
9 HT24 TAG GGT TAG GGT TAG GGT TAG GGT
10 24bcl CGG GCG CGG GAG GAA GGG GGC GGG
11 cmyc GGG GAG GGT GGG GAG GGT GGG GAA GGT GGG G
aﬃnity for several DNA G-quadruplex structures, especially
those sequences found in the promoter regions of c-myc [16]
and bcl-2 [17, 18] oncogenes.
2. Materials and Methods
2.1. Chemicals. The phosphoramidites and ancillary reagents
used during oligonucleotide synthesis were obtained from
Applied Biosystems (USA) and Link Technologies Ltd.
(Scotland). The rest of the chemicals were purchased
from commercial sources. The Slide-A-Lyzer Mini Dial-
ysis Units 3500 MWCO were purchased from Pierce.
Acridine-9-carboxylic acid was obtained from Aldrich. 2-
(Acridine-9-carboxamide)acetic acid was prepared by reac-
tion of acridine-9-carboxylic acid with glycine methyl
ester and subsequent saponification of the methyl ester
as described [10]. Boc-(2-aminoethyl)glycine(Fmoc) (Boc-
Aeg(Fmoc)-OH) was obtained from Iris Biotech and Fmoc-
glycine (Fmoc-Gly-OH) was obtained from Bachem. Boc-6-
aminohexyl hemisuccinate was prepared by reaction of Boc-
6-aminohexanol with succinic anhydride.
2.2. Oligonucleotide Synthesis. Oligonucleotide sequences
(Table 1) were prepared on an automatic Applied Biosystems
3400 DNA synthesizer on 1 μmoL (CPG resin) scale using
commercially available 2-cyanoethyl phosphoromidites.
After the assembly of the sequences, oligonucleotide-
supports were deprotected using 32% aqueous ammonia
at 55◦C for 16 h. Ammonia solutions were concentrated to
dryness and the residue was desalted by a NAP-10 (Sephadex
G-25) column.
2.3. Solid-Phase Synthesis of Acridine Oligomers. Acridine
dimers and trimers (1–4, Figure 1) were prepared with
the 2-aminoethylglycine scaﬀold, which allows the growth
of a polyamide skeleton on solid-phase and the following
incorporation of acridine unit.
The assembly of 2-aminoethylglycine derivatives was car-
ried out on methylbenzhydrylamine (MBHA) polystyrene-
1%-divinylbenzene solid support applying an Fmoc/Boc
hybrid strategy using Boc-Aeg(Fmoc)-OH, Fmoc-Gly-OH,
and acridine-9-carboxylic acid as building blocks (Figure 2).
Fmoc-Sarcosine-OH (5 eq) was coupled to the resin
using standard coupling conditions (5 eq. PyBOP and 10 eq.
DIEA, 1 h), then the Fmoc group was removed (20% of
piperidine in DMF, 30 min), and Boc-6-aminohexyl hemi-
succinate (Boc–NH–(CH2)6–OCOCH2CH2COOH) was
coupled (5 eq R-COOH, 5 eq. PyBOP and 10 eq. DIEA, 1 h)
to the support. The residual unreacted amino groups were
acetylated with 5 eq. of acetic anhydride and 5 eq. of DIEA.
Next, the Boc group was removed (40% trifluoroacetic
acid in dichloromethane) and the 2-aminoethylglycine
skeleton was synthesized by repetitive couplings of Boc-
Aeg(Fmoc)-OH until reaching the desired dimer or trimer
compound. The last Boc group of the sequence was removed
and the resulting amino group was acetylated (5 eq. acetic
anhydride and 5 eq. DIEA).
Once the aminoethylglycine backbone was built, the
Fmoc-protecting groups of the side chains were removed
(20% of piperidine in DMF, 30 min), and Fmoc-Gly-
OH followed by 9-acridine carboxyl acid was coupled to
the support. The progress of the coupling reactions was
followed by ninhydrine test and by UV monitoring of the 9-
methylene-9H-fluorene released during deprotection, which
allowed optimization of the coupling conditions.
The acridine dimer 1 and trimer 3 were obtained
by treatment of the appropriate solid supports with HF
anhydrous at 0◦C. Finally the acridine dimer 2 and trimer
4 were obtained by treatment of dimer 1 and trimer 3
respectively with 32% aqueous ammonia (1 h, 55◦C).
Good yields and purities were obtained for the products
(around 85% for 1 and 2, 75% for 3 and 4). HPLC and
MALDI-TOF spectra are shown in Supplementary Material
available onlie at doi: 10.4061/2010/489060.
The compounds were analyzed by MALDI-TOF, 1
[M+Na+] = 1080.3 (expected 1054.2), 2 [M] = 885.2
(expected 884.0), 3 [M] = 1418.9 (expected 1416.5), and 4
[M] = 1247.4 (expected 1246.4). MALDI-TOF spectra were
obtained using a Perseptive Voyager DETMRP mass spec-
trometer, equipped with nitrogen laser at 337 nm using a 3 ns
pulse. The matrix used contained 2,5-dihydroxybenzoic acid
(DHB, 10 mg/mL in water).
Analytical HPLC was performed using XBridge OST C18
(Waters), 2.5 μm, 4.6 × 50 mm column using a 10-minute
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Figure 1: Structure of the acridine derivatives prepared.
linear gradient from 9% to 45% B, flow rate 1 mL/min;
solution A was 5% ACN in 0,1 M aqueous TEAA, and B 70%
ACN in 0.1M aqueous TEAA. HPLC chromatograms and MS
spectra can be found in Supplementary Material.
Fluorescence spectra were recorded using a Jasco FP-6200
spectrofluorometer equipped with a Peltier temperature
controller, λem = 435 nm (λexc = 252 nm).
UV spectra were recorded using a Jasco spectrophotome-
ter V-650, λmax = 252 nm, 360 nm.
2.4. Cell Viability Assays. The in vitro cytotoxicity of the
compounds (Figure 1) was evaluated by colorimetric assays
with tetrazole salts (MTT) on Jurkat clone E6-1 (human
leukemia), GLC-4 clone (human lung carcinoma) cell lines,
and one mouse fibroblast cell line (NIHT-3T3).
GLC4 and Jurkat cell lines were cultured in RPMI and
NIH3T3 in DMEM and supplemented with 10% fetal calf
serum, 10000 u/mL penicillin, 10 μg/mL streptomycin and
200 mM L-glutamine. Cells were grown in a humidified
atmosphere of air containing 5% CO2 at 37◦. Cells were
plated in triplicate wells (1.5·104 cells well) in 100 μL
of growth medium in 96-well plates and proliferate for
24 h and then treated with increasing concentrations of
acridine oligomers. After 72 h of incubation, 10 μM of MTT
(5 mg/mL in Phosphate buﬀer saline 10%) was added for
an additional 4 h. The absorbance at 570 nm was measured
on a multiwell plate reader after addition of 100 μl of
isopropanol : 1N HCl (24 : 1). Cell viability was expressed
as a percentage of control and IC50 was determined as the
concentration of drug that produced a 50% reduction of
absorbance at 570 nm.
2.5. Competitive Dialysis Assays. 100 μL of a 50 μM oligonu-
cleotide (Table 1) in potassium phosphate buﬀer (185 mM
NaCl, 185 mM KCl, 2 mM NaH2PO4, 1 mM Na2EDTA,
6 mM Na2HPO4 at pH 7) was introduced into a separated
dialysis unit. A blank sample containing only buﬀer without
oligonucleotide was also prepared. All 12 dialysis units were
then placed in the beaker containing the 1 μM solution
of the appropriate acridine derivative. The samples were
allowed to equilibrate with continuous stirring at room
temperature overnight. After the equilibration period, DNA
samples were removed to an Eppendorf tube. SDS is usually
added to denature the DNA sample and release the acridine
oligomer, but in our case the presence of K+ ions induced the
formation of a white precipitate, which interfered with the
measurement of the fluorescence spectra of the samples.
In order to measure the compound retained in the
dialysis unit, samples were treated with snake-venom phos-
phodiesterase to degrade the DNA and release the acridine
oligomer. 350 μL of potassium phosphate buﬀer (without
EDTA), buﬀer at pH 8.5, 50 μL of 100 mM MgCl2, and
1 μm of snake venom phosphodiesterase solution were added
for an additional overnight incubation at 37◦C. Finally, the
fluorescence of each sample was measured (λex and λem were
set to 252 and 435 nm, resp.).
2.6. Fluorescence Assays. The study of the interaction equilib-
rium of acridine derivatives and oligonucleotides consists of
recording the fluorescence spectra of a 0.2 μM solution of the
acridine derivative after the addition of increasing amounts
of oligonucleotide (from 0 to 10 μM) in potassium phosphate
buﬀer (185 mM NaCl, 185 mM KCl, sodium phosphate,
1 mM EDTA, pH 7). These experiments were carried out by
adding small volumes of an oligonucleotide stock solution
to the 0.2 μM solution of the acridine derivative. After 24 h
the emission spectra of the resulting solutions were recorded
from 300 to 500 nm at 252 nm excitation wavelength at 25◦C.
The macroscopic binding constant (K) corresponding to
the reaction
DNA + ligand−−→← Interaction complex (1)
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Figure 2: Solid-phase synthesis of dimer and trimer acridine derivatives. (a) (i) Fmoc-Sar-OH, PyBOP, DIEA; (ii) 20% piperidine, DMF;
(iii) Boc–NH–(CH2)6–OCH2CH2COOH, PyBOP, DIEA; (b) (i) 40% TFA, DCM; (ii) Fmoc-Aeg(Boc)-OH, PyBOP, DIEA; (iii) Repeat steps
(i) and (ii) n times; (c) (i) 40% TFA, DCM; (ii) Ac2O, DIEA, DMF; (d) (i) 20% piperidine, DMF; (ii) Fmoc-Gly-OH, PyBOP, DIEA; (e) (i)
20% piperidine, DMF; (ii) acridine-9-carboxylic acid, PyBOP, DIEA; (f) anhydrous HF (0◦); (g) 32% aqueous NH3.
was calculated from the multivariate analysis of fluorescence
data recorded in the range 300–390 nm using the hard-
modeling program Equispec [19]. This program performs a
nonlinear least squares optimization of K and of the pure
fluorescence spectra corresponding to each of the species
considered (DNA, ligand, and interaction complex). A 1 : 1
stoichiometry DNA : ligand for the interaction complex was
assumed. The logarithms of the binding constants calculated
are given as their weighted means with twice their standard
errors (units of the least significant digit). Results are shown
in Table 2.
2.7. Circular Dichroism. An increasing amount of 1 (from
0 to 8 μM) in potassium phosphate buﬀer (185 mM NaCl,
185 mM KCl, sodium phosphate, 1 mM EDTA, pH 7) was
added to a 1 μM solution of the oligonucleotide. The
CD spectra were recorded after 24 h on a Jasco J-810
spectropolarimeter attached to a Julabo F/25HD circulating
water bath in 1 cm path-length quartz cylindrical cells, using
a 50 nm/min scan rate, a spectral band width of 1 nm, and
a time constant of 4 s. All the spectra were corrected with
the buﬀer blank, normalized to facilitate comparisons and
noise-reduced using Matlab software. CD spectra are shown
as supplementary data.
3. Results and Discussion
3.1. Synthesis of Acridine Oligomers. The synthesis of acridine
dimer and trimers has been described previously [13]
using a Boc-(2-aminoethyl)glycine derivative carrying the
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Table 2: Logarithm of the binding constants (log K) calculated from data recorded throughout fluorescence titrations using Equispec
program assuming a 1 : 1 stoichiometry DNA : ligand for the interaction complex (details in materials and methods). Compounds 1–4
correspond to the acridine dimers and trimers prepared in this study. HT24, 24bcl, cmyc, and Dickerson correspond to oligonucleotide
sequences shown in Table 1.
1 2 3 4
HT24 4.9 ± 0.4 4.6 ± 0.5 5.3 ± 0.3 n.d.
24bcl 6.8 ± 0.5 5.1 ± 0.1 5.3 ± 0.2 n.d.
cmyc 5.5 ± 0.3 4.9 ± 0.2 4.8 ± 0.5 5.3 ± 0.2
Dickerson n.d. n.d. n.d. n.d.
n.d. not determined.
2-(acridine-9-carboxamide)acetyl residue. The synthesis of
this monomer was long and yields were low.
An alternative method developed is to first assemble
the Boc-(2-aminoethyl)glycine backbone on solid-phase,
and then the intercalating agent is added. This strategy is
more convenient for rapid synthesis, as it is unnecessary to
construct each intercalating monomer.
Thus, acridine oligomers were assembled using the
methylbenzhydrylamine (MBHA) resin by applying an
Fmoc/Boc hybrid strategy and using Boc-(2-aminoethyl)-
(Fmoc)glycine [Boc-Aeg(Fmoc)-OH] as building block
(Figure 2). The Boc group was used to protect the aminoethyl
group of each unit, which thus facilitated elongation of
the backbone. Fmoc was the semipermanent protecting
group for the amino group of glycine through which the
intercalating compound was introduced. The succinyl linker
was selected to connect the solid support and the oligomer.
This linker is used in oligonucleotide synthesis and it is labile
to ammonia. Unfortunately, the linker is not compatible with
Fmoc chemistry. It has been described that an intramolecular
side reaction can lead to premature loss of the oligomers
during the base treatment used to remove the Fmoc group
[20]. Thus, N-methylglycine (sarcosine) was incorporated
between the amino-support and the succinyl linker. The
presence of the N-methyl group prevents the potential side
reaction [20]. 6-Aminohexanol was used to connect the
succinyl linker and the oligomer backbone, as described for
the synthesis of peptide nucleic acid (PNA) oligomers [21].
The (2-aminoethyl)glycine backbone was assembled by
consecutive additions of Boc-Aeg(Fmoc)-OH to obtain the
dimer and trimer sequence. Acetylation of the N-terminal
position was carried out using acetic anhydride and a base.
Next, the removal of the Fmoc group allowed the
addition of a Fmoc-glycine unit as a spacer, which was
followed by the addition of acridine-9-carboxylic acid. The
acridine dimer and trimer were synthesized in this way
(Figure 2).
After assembly of the oligomers, the resulting supports
were treated with ammonia. The desired oligomers were
not released from the support even after prolonged time
and high temperatures. We therefore treated the supports
with anhydrous HF to yield the acridine oligomers 1 and
3, which contain the sarcosyl succinyl linker. At this point
HPLC spectra showed a major peak that had the expected
molecular weight for the oligomers 1 and 3 carrying the
sarcosyl succinyl linker (see supplementary data). This
observation indicates that the simultaneous incorporation
of all acridines proceeded with excellent yields. Ammonia
treatment of acridines 1 and 3 in solution now yielded the
desired acridine dimer 2 and trimer 4 in excellent yields and
purity (see supplementary data). Compounds 1–4 were fully
characterized and their properties were analyzed.
The pKa of the acridine ring of acridine-9-carboxylic acid
and 2-(acridine-9-carboxamide)acetic acid was measured by
UV titration. pKa of acridine-9-carboxylic acid was 5.5 ±
0.1 and 2-(acridine-9-carboxamide)acetic acid 4.1± 0.2. We
therefore estimated that the acridine rings of compounds 1–4
are mainly unprotonated at pH 7.0.
3.2. Cell Viability Assay. The in vitro cytotoxicity of the com-
pounds was evaluated by colorimetric assays with tetrazole
salts (MTT). This assay is based on the capacity of living
cells to incorporate and reduce MTT. This reaction can be
followed by the change of absorbance of the reduced and
oxidized forms. This reaction is done by the action of the
mitochondrial enzyme succinatehydrogenase, which is active
only in living cells. The intensity of color is directly correlated
with the number of living cells in the sample. No cytotoxicity
activity was observed in compounds 1–4 at concentrations
up to 50 μM.
3.3. Competitive Dialysis Studies. In order to evaluate the
selectivity of the compounds for DNA structures, a compet-
itive dialysis experiment was performed using 11 oligonu-
cleotides (Table 1) representing several nucleic acid struc-
tures [22]. The more acridine accumulated in the dialysis
unit indicates a higher binding aﬃnity to the oligonucleotide
present in the dialysis unit. As model for single stranded
structures we used T20 and the C-rich complementary strand
of bcl-2 (24bclc). This last oligonucleotide folds in an i-form
quadruplex structure at acidic pH but has no structure in
the conditions used in the dialysis (pH 7) [18]. As duplexes
we used the self-complementary sequences Dickerson-Drew
dodecamer (Dickerson) and a 26 mer (ds26). A parallel
triplex (TC triplex) and an antiparallel triplex (GA triplex)
were also prepared by mixing a hairpin Watson-Crick
sequence and the corresponding triplex-forming sequence.
Finally, the following G-quadruplex sequences were pre-
pared: the tetramolecular parallel G-quadruplex TG4T [23],
the antiparallel thrombin-binding aptamer (TBA) [24], the
human telomere sequence (HT24) [25], and the promoter
sequences of c-myc (cmyc) [16] and bcl-2 (24bcl) [17, 18].
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Figure 3: Results obtained by the competitive dialysis assay. The amount of ligand bound to each DNA structure is shown as a bar graph. The
fluorescence of each sample was measured using an excitation wavelength of 252 nm and an emission wavelength of 435 nm, respectively.
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Figure 4: Fluorescence titration spectra. Fluorescence spectra of a 0.2 μM solution of the acridine derivative after the addition of increasing
amounts of oligonucleotide (from 0 to 10 μM) in potassium phosphate buﬀer. Excitation wavelength is 252 nm.
We used the protocol described by Ren and Chaires
[26] with a few modifications. The buﬀer solution was
similar to that described in [26] but K+ was included
(185 mM) to ensure the formation of the most stable G-
quadruplex structures. At the end of the dialysis experiment,
the amount of acridine derivative bound to the DNA
was analyzed by fluorescence measurement of the acridine
compound. After dialysis, we observed that the spectra of
the acridine derivatives of some samples (especially those
from G-quadruplexes) diﬀered greatly from the fluorescence
spectra of the initial compounds. This diﬀerence is attributed
to the interaction of the acridine derivatives with the G-
quadruplex. In order to release the acridine oligomer, the
addition of SDS is recommended [26, 27]. Using SDS, the
presence of K+ ions resulted in the formation of a white
precipitate with SDS which did not allow the measurements
of the fluorescence spectra [27]. In order to solve this
problem, the oligonucleotide was digested with snake venom
phosphodiesterase at the end of the dialysis experiment.
Thus, the fluorescence spectra of the acridine derivatives
were recorded with high accuracy without the interference
of DNA and without the use of SDS.
We measured the binding preferences of compounds 1–4
and the acridine monomers acridine-9-carboxylic acid and
2-(acridine-9-carboxamide)acetic acid (Figure 1). Acridine-
9-carboxylic acid showed aﬃnity only for duplex ds26
(Figure 3). Unexpectedly, the addition of the glycine residue,
used as spacer, induced a change in the aﬃnity. 2-(Acridine-
9-carboxamide)acetic acid showed the highest aﬃnity for the
G-quadruplex sequences cmyc and 24bcl and less aﬃnity for
duplex ds26.
Dimer 1 (dimer with the sarcosylsuccinyl linker) has a
similar profile as 2-(acridine-9-carboxamide)acetic acid. In
this case, the G-quadruplex 24bcl is preferred to the cmyc
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sequence. Some aﬃnity for the TC triplex is observed but no
aﬃnity for duplex ds26. Surprisingly, dimer 2 (without the
sarcosylsuccinyl linker) lost most of the selectivity although
some residual higher aﬃnity for G-quadruplex 24bcl was
observed.
In contrast, trimer 3 (trimer with the sarcosylsuccinyl
linker) presented lower binding aﬃnity than the other
compounds. However, trimer 4 (without the sarcosylsuccinyl
linker) recovered most of the aﬃnity for 24bcl and cmyc
showing a similar profile to that observed for dimer 1.
3.4. Measurement of G-Quadruplex-Aﬃnity Constants by
Fluorescence Spectroscopy. Dialysis experiments suggest that
some of the acridine derivatives prepared have special aﬃnity
for 24bcl and cmyc G-quadruplexes. In order to confirm this
observation, binding constants were estimated using mole-
ratio experiments monitored with fluorescence spectroscopy.
Hence, increasing amounts of oligonucleotides 24bcl, HT24,
cmyc, and Dickerson were added to a solution with a
fixed concentration of the acridine derivatives, and the
fluorescence spectra were recorded at excitation wavelengths
252 and 360 nm.
At both wavelengths, changes in the fluorescence spec-
tra upon the addition of oligonucleotides were observed.
Figure 4 shows the changes in the fluorescence spectra of
acridine dimer 1 at excitation wavelengths 252 nm when
oligonucleotides 24bcl, HT24, cmyc, and Dickerson were
added. A dramatic increase in fluorescence intensity was
observed around 360 nm upon addition of G-quadruplex
DNA sequences (24bcl, HT24, and cmyc). The greatest
changes were seen with 24bcl and cmyc. Similar results
were found with compounds 2, 3, and 4 as well as
2-(acridine-9-carboxamide)acetic acid (see supplementary
data). Interestingly, when the Dickerson dodecamer was
added, no changes in the fluorescence spectra were detected.
The progressive modification of the fluorescence spectrum
of these compounds reflects their interaction with the G-
quadruplex.
Fluorescence data obtained at an excitation wavelength of
252 nm were analyzed with the hard-modelling EQUISPEC
program in order to calculate the corresponding binding
constants (Table 2). The values of the logarithm of the bind-
ing constant (logK) obtained lie in the range 4–6, suggesting
a weak interaction with DNA. Of all the compounds, dimer
1 showed the highest binding constants, thereby suggesting
a stronger interaction with DNA than the other compounds
studied. However these values were slightly lower than the
binding constants calculated for other similar ligands, such
as the acridine monomers BRACO-19 (logK = 7.4) and
BSU6048 (logK = 6.5) [28] or a hemicyanine-peptide ligand
(logK = 7.1 [29]), when interacting with human telomere
quadruplex.
Changes in the fluorescence spectra at an excitation
wavelength of 360 nm were also recorded. Fluorescent emis-
sion at this wavelength 360 nm was much lower than that
recorded at 252 nm; so the fluorescent signal was low. Upon
addition of the oligonucleotide to a solution of compounds
1–4, the formation of a new maximum at 442 nm was
observed (see supplementary data). Although the fluorescent
intensity was low, we could estimate the binding constant of
the stronger interactions of compound 1 with 24bcl (7.2 ±
0.4) and cmyc (5.5±0.2) sequences (see supplementary data).
These values are in agreement with those recorded at an
excitation wavelength of 252 nm (Table 1).
Finally, CD spectra of the DNA : ligand mixtures showed
no significant diﬀerences in relation to those of DNA (see
supplementary data). This observation suggests that the
DNA G-quadruplex structure is not altered significantly
upon binding of the acridine derivatives.
4. Conclusions
In summary, here we have described a new optimized
protocol for the synthesis of acridine oligomers with a (2-
aminoethyl)glycine backbone. In this method, the Boc-(2-
aminoethyl)glycine backbone is first assembled on solid-
phase, and then the intercalating agent is assembled on the
backbone. This strategy is faster and more eﬃcient than
the one described previously [13] and yields the desired
oligomers with good yields. A succinyl linker was used to
connect the oligomers to the solid support. The succinyl
linker attached to sarcosine was unexpectedly too stable and
oligomers could not be directly released from the support by
a single ammonia treatment. Instead a two-step protocol was
used obtaining the desired compounds and an intermediate
oligomer carrying a long succinyl sarcosine chain at the C-
terminal position.
Competitive dialysis experiments have shown diﬀerences
on the aﬃnity of acridine oligomers to G-quadruplexes.
Higher aﬃnities are found in G-quadruplex sequences
present on the promoter regions of c-myc and bcl-2 onco-
genes. This aﬃnity is modulated by the number of acridines
and the presence of the succinyl sarcosine chain at the C-
terminal position, dimer 1 and trimer 4 being the more rele-
vant compounds for G-quadruplex binding. The monomer
2-(acridine-9-carboxamide)acetic acid also shows binding
properties of interest and it is the simplest compound to
be prepared. Unfortunately, the compounds synthesized in
this study did not have antiproliferative activity in spite
of their aﬃnity to quadruplex. This observation contrasts
with other reported quadruplex-binding acridine derivatives,
such as BRACO-19 [11, 30] which shows anticancer activity.
The lower aﬃnity to telomere G-quadruplex sequence and
the larger size of the acridine derivatives described in the
present study may hinder cellular uptake and may explain
the absence of antiproliferative activity.
The acridine nucleus is described to interact to G-
quadruplex. Depending on the substituents, the acridine
nitrogen can be charged when bound to DNA, and with the
ring stacked on a G-tetrad, the charge will occupy a position
similar to that of the potassium cation that stabilizes the G-
quadruplex [28]. The introduction of protonable side chains
on the acridine ligand enhances binding by electrostatic
interactions [28]. In our case the acridines had no protonable
substituents and the acridine nitrogen was not charged when
bound to DNA. For this reason, the aﬃnity of oligomeric
acridines to G-quadruplexes is due to the multimeric nature
of the compounds as well as the addition of a glycine
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to acridine-9-carboxylic acid. An interesting possibility for
future development is the introduction of protonable sites
at the oligomeric acridines, which may increase solubility
in water, aﬃnity to target, and cellular uptake. The method
described here will contribute to accelerating the preparation
of potential active oligomeric compounds.
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